Wainua Fails Pivotal ATTR-CM Trial; Ionis Sinks 20%

GSK just walked away from Alector — tearing up a partnership once worth two-point-two billion dollars, and with it, the whole story of GSK's comeback in neuroscience.

And that's before you get to the FDA — rejection letters are public again, fourteen of them at once, Hengrui and Elevar got a third no on liver cancer, Sanofi finally cleared subcutaneous Sarclisa, and Moderna gave back double digits in a day. It's a loaded Friday. Let's get into it.

Welcome to The Pharma Closeout for Friday, July 10th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Good to have you with us.

Start with GSK and Alector. GSK is ending an immuno-neurology alliance that carried up to two-point-two billion dollars in potential value at signing. And this wasn't a side bet — this deal was GSK planting a flag that said, we are back in the brain.

Which is exactly why it stings. GSK spent years out of CNS after a string of failures. Alector was the re-entry vehicle — the bet that tuning the brain's immune response could slow neurodegeneration. That thesis is the thing that just broke.

And it broke on the data. The reporting is blunt: clinical setbacks derailed it. The immuno-neurology bet, in Endpoints' words, fizzled. So GSK is handing the programs back rather than funding the next stage.

OK, but I'd push back on the "GSK retreats from neuroscience" framing that's going around. There's no evidence of a broad neuro build here to retreat from. This reads as one thesis failing — and walking after the data disappoints is discipline, not a white flag.

That's fair. So the sharper cut isn't "GSK quits the brain." It's that the re-entry was concentrated in a single bet — and when that bet failed, there was no second leg to stand on.

And that's the lesson worth carrying. Look at the calendar: this drops the same week Roche scrapped two Ionis-partnered Huntington's programs, including tominersen. Different mechanism, different modality — same verdict. CNS translational risk hasn't moved an inch. Two marquee neuro bets reset inside five days, and neither one could have seen the other coming.

The competitive read: if you run BD in neuroscience, the takeaway isn't "avoid the brain." It's that partnered CNS assets are getting handed back faster now — which means the walk-away clauses and the milestone triggers matter more than the headline biobucks. That two-point-two billion? Never the number that counted.

And for Alector, the real question starts Monday — is there a pipeline story left once the big-pharma checkbook walks out the door? That's the thread.

Let's stay on capital, because it's moving in every direction today. Apnimed filed for a Nasdaq IPO — and the timing is the whole play. They filed while the FDA is actively reviewing their oral sleep apnea drug, AD109. That's a company pricing an offering against a live approval catalyst.

It's a confident move, and it fits the tape. The biotech IPO window's been reopening all year. Filing into a pending decision tells you management likes the readthrough — clear the drug, and they've got an oral option in a market that's been all devices. Miss, and they've raised straight into a hole.

And they're not alone in the water. Vertex just closed its ten-billion-dollar Crinetics buy — its clearest step yet into endocrine disease — and Lilly's been stacking deals to match its own scale. On the pipeline side, though, it wasn't all green: AstraZeneca and Ionis took a hard one, their Phase 3 heart study in transthyretin cardiomyopathy missing its primary endpoint. AstraZeneca dropped nine percent on it.

And that's a rare miss for AstraZeneca — which is the point. It's the second Ionis-partnered program to blow up this week, right alongside the Roche Huntington's news. Two very different disease areas, same partner, same week. If you're an Ionis shareholder, you're not reading two stories — you're reading one about platform risk.

Then there's the other half of the tape. Moderna fell about eleven percent — ImmunityBio and Sarepta both off eight — in a broad biotech selloff. No company-specific news anywhere. Just profit-taking after a parabolic run. Moderna was up a hundred and sixty percent year to date going into today.

The trigger was a single note — JPMorgan's Jessica Fye reaffirmed a sell and named Moderna one of twenty-five stocks to short into the third quarter. But the tell isn't the downgrade. It's that large-cap pharma barely blinked. Lilly down three, J&J off one. That gap is the story — money rotating out of high-beta biotech into defensive names.

So one analyst didn't sink a sector.

No. When the year's best performers sell off on nothing, that's positioning unwinding — and it means the next real catalyst gets judged against a jumpier, far less forgiving tape.

On the regulatory front, the structural story of the day: the FDA is publishing drug rejection letters again. Fourteen posted at once on Friday — after the agency paused the practice back in April, when a pharma-backed citizen petition argued it risked exposing proprietary information. That pause is done.

And HHS is separately laying the groundwork to lock it in through rulemaking. So this stops being a policy someone can quietly switch off — and becomes a rule.

That changes how companies write the press release. Once a rejection reliably lands in public, you draft your CRL announcement assuming the actual letter is sitting right next to it. And the timing here is pointed — because one of those fourteen is the marquee rejection of the day. Hengrui and Elevar got turned down a third time on their PD-1 VEGFR combination in first-line liver cancer. This round, on manufacturing site deficiencies.

Third no in two years. Same combination.

And there's the tell. This stopped being an efficacy story a long time ago — the data supported the filing. It's a manufacturing problem they haven't solved across three cycles, and that's a far deeper credibility hole with the agency than a data question ever is. Now, two on the approval side to move quickly: the FDA broadened the Padcev-Keytruda combination to more muscle-invasive bladder cancer patients, extending that franchise's lead. And Sanofi finally landed its subcutaneous Sarclisa nod through an on-body injector after an earlier delay — a genuine convenience lever against the other anti-CD38 agents in myeloma.

One more you flagged — Vera Therapeutics.

Right — Vera won its FDA nod in IgA nephropathy, which sets up a direct commercial fight with Otsuka, who got there first last year. Second entrant, same disease. But zoom out, and the two threads of the day collide: the transparency shift lands the same afternoon as that third Hengrui letter.

Bad week to have a paper trail.

That's the uncomfortable implication for anyone carrying a complicated manufacturing story. Your rejection letters are about to be searchable — and "manufacturing deficiencies," in writing, three times over, is the kind of record that follows an asset from room to room.

Looking ahead — the nearest catalyst is Corcept. FDA decision expected tomorrow in platinum-resistant ovarian cancer. That's the next binary on the board.

And further out, Moderna's flu vaccine — mRNA-1010 — has an FDA action date on August 5th. After today's selloff, that date just became a much higher-stakes event for the stock than it looked a week ago.

And a callback worth making — Lilly's Foundayo, orforglipron, approved back in April, is still running what Fierce called a "muted" launch. The oral GLP-1 was supposed to reset the obesity market. The ramp is slower than the hype promised.

Which is the durability question wearing a different coat. Approval was never the hard part for oral GLP-1s — it's adherence and access once the novelty burns off. A muted launch this early tells you something the trial data never could: the real-world uptake curve. That's the one to track.

And that is your Pharma Closeout for Friday, July 10th — and what a week it was. GSK unwound the Alector bet, the FDA switched the rejection-letter lights back on, Hengrui caught its third no, AstraZeneca and Ionis took a Phase 3 hit, Sanofi finally cleared subcutaneous Sarclisa, and Moderna gave back a chunk of a monster year. This industry does not slow down — and honestly, we love it. If someone on your team needs to be across this week in pharma, send them the feed — and if this briefing saves you time, follow us on Spotify and drop a rating.

Go enjoy your weekend — keep half an eye on Corcept tomorrow. We'll be back Sunday with the Weekend Closeout. See you then!